1. Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis▿
- Author
-
Jose F. Garcia-Bustos, Joaquín Rullas, Manuela Beltran, Neus Cáceres, Iñigo Angulo-Barturen, Juan Ignacio García, and Pere-Joan Cardona
- Subjects
Drug ,Tuberculosis ,media_common.quotation_subject ,Moxifloxacin ,Antitubercular Agents ,Pharmacology ,Mycobacterium tuberculosis ,Mice ,Acetamides ,Drug Discovery ,medicine ,polycyclic compounds ,Isoniazid ,Animals ,Pharmacology (medical) ,Experimental Therapeutics ,Tuberculosis, Pulmonary ,Ethambutol ,Oxazolidinones ,media_common ,Aza Compounds ,Inhalation Exposure ,biology ,business.industry ,Linezolid ,Reproducibility of Results ,Pyrazinamide ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,biology.organism_classification ,bacterial infections and mycoses ,Mice, Inbred C57BL ,Disease Models, Animal ,Infectious Diseases ,Quinolines ,Rifampin ,business ,Immunocompetence ,Rifampicin ,medicine.drug ,Fluoroquinolones - Abstract
Murine models of M ycobacterium tuberculosis infection are essential tools in drug discovery. Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice. This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.
- Published
- 2010